Profesionales médicos

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estado, etc.

1. A Study to Evaluate Noninvasive Ultrasound Elastography of Kidney and Lung in Assessment of Volume Status in ICU Patients

   Rochester, Minn.

   The primary purpose of this study is to assess the feasibility of performing lung and kidney and lung ultrasound elastography among patients with critical illness from different etiologies that could be associated with volume overload.

2. A Study to Evaluate the Use of Bedside Echo for the Assessment of Right Ventricular Function in Hypoxemic Respiratory Failure and ARDS

   Rochester, Minn.

   The purpose of this study is to evaluate the use of a non-invasive bedside echocardiography to assess the effect of mechanical ventilation (invasive and non-invasive) on the function of the heart.

    

    

3. ARrest RESpiraTory Failure From PNEUMONIA

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to establish the effectiveness of a combination of an inhaled corticosteroid and a beta agonist compared to placebo for the prevention of acute respiratory failure (ARF) in hospitalized patients with pneumonia and hypoxemia.

4. Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

   Rochester, Minn.

   The purpose of this study is to determine the efficacy of abatacept compared to placebo for treatment of subjects with GLILD in the context of CVID.

   There is no standard of care therapy for patients with granulomatous-lymphocytic interstitial lung disease (GLILD) seen in common variable immunodeficiency (CVID). Abatacept has recently looked promising for the treatment of patients with complex CVID.

5. A Study to Evaluate the Effectiveness of Psychological Support Based on Positive Suggestions on Mental Health Morbidity and Cognitive Function

   Rochester, Minn.

   The purpose of this trial is to compare the effectiveness of psychological support based on positive suggestions (PSBPS) vs. usual care on mental health morbidity and cognitive function in survivors of critical illness.

6. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

   Rochester, Minn.

   The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

    

7. A Biorepository to Study Portopulmonary Hypertension

   Rochester, Minn.

   We propose to develop a biorepository of plasma samples from patients with suspected and confirmed portopulmonary hypertension to improve our understanding of this disease and its response to pulmonary arterial hypertension targeted therapy and liver transplantation.

8. In-home Versus In-Clinic Subcutaneous Nivolumab Administration through Connected and Remote Cancer CARE Beyond Walls

   Jacksonville, Fla.

   The purpose of this study is to evaluate the impact of the location of SQ Nivo administration, at the infusion center or in the home, on patient preference and acceptability, safety, patient reported outcomes (PROs), and clinical outcomes.

9. A Study to Identify Discomforts Among Intensive Care Unit Patients

   Rochester, Minn.

   The primary purpose of this study is to assess and describe the contributing sources of discomfort(s) experienced by ICU patients utilizing the Discomforts Perceived by ICU Patients instrument, a modified version of the Inconforts des Patients de REAnimation questionnaire (IPREA).

10. A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients

    Jacksonville, Fla.

    The purpose of this study is to demonstrate the effect of ralinepag the time to first adjudicated clinical worsening event in subjects with pulmonary arterial hypertension (PAH).Clinical worsening event is defined as 1 of the following: death, nonelective hospital admission of <24 hours due to worsening PAH or RHF, initiation of parenteral or inhaled therapy, disease progression, or unsatisfactory long term clinical response.